Part 2: A Phase 2a Single Blind, Multiple Dose Escalation, Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LQT-1213 in Patients Diagnosed With Long QT Syndrome Type 2 and Type 3.
Part 2: A Phase 2a Single Blind, Multiple Dose Escalation, Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LQT-1213 in Patients Diagnosed With Long QT Syndrome Type 2 and Type 3.
